Xuefeng Yan1,2,3, Gang Niu2, Zhe Wang2, Xiangyu Yang2, Dale O Kiesewetter2, Orit Jacobson4, Baozhong Shen5,6, Xiaoyuan Chen7. 1. Department of Radiology, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, China. 2. Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, USA. 3. Molecular Imaging Center of Harbin Medical University, Harbin, Heilongjiang, China. 4. Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, USA. orit.jacobsonweiss@nih.gov. 5. Department of Radiology, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, China. shenbzh@vip.sina.com. 6. Molecular Imaging Center of Harbin Medical University, Harbin, Heilongjiang, China. shenbzh@vip.sina.com. 7. Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, USA. shawn.chen@nih.gov.
Abstract
PURPOSE: Chemokine receptor CXCR4 plays an important role in tumor aggressiveness, invasiveness, and metastasis formation. Quantification of CXCR4 expression by tumors may have an impact on prediction and evaluation of tumor response to therapies. In this study, we developed a robust and straightforward F-18 labeling route of T140, a CXCR4 peptide-based antagonist. PROCEDURES: T140 derivative was conjugated to 1,4,7-triazacyclononane-triacetic acid (NOTA) and labeled with Al[(18)F]. Al[(18)F]NOTA-T140 was evaluated in vitro in cell-based assay and stability in mouse serum and in vivo using CXCR4 positive and negative tumor xenograft models. RESULTS: Labeling of Al[(18)F]NOTA-T140 was completed within 30 min with a radiochemical yield of 58 ± 5.3 % at the end of synthesis, based on fluoride-18 activity. Al[(18)F]NOTA-T140 accumulated in CHO-CXCR4 positive but not negative tumors. Al[(18)F]NOTA-T140 uptake in the tumors correlated with CXCR4 protein expression. Moreover, Al[(18)F]NOTA-T140 had high accumulation in CXCR4-positive metastatic tumors. CONCLUSIONS: The simplicity of Al[(18)F]NOTA-T140 labeling along with its properties to specifically image CXCR4 expression by tumors warrant further clinical application for the diagnosis of CXCR4 clinically.
PURPOSE: Chemokine receptor CXCR4 plays an important role in tumor aggressiveness, invasiveness, and metastasis formation. Quantification of CXCR4 expression by tumors may have an impact on prediction and evaluation of tumor response to therapies. In this study, we developed a robust and straightforward F-18 labeling route of T140, a CXCR4 peptide-based antagonist. PROCEDURES: T140 derivative was conjugated to 1,4,7-triazacyclononane-triacetic acid (NOTA) and labeled with Al[(18)F]. Al[(18)F]NOTA-T140 was evaluated in vitro in cell-based assay and stability in mouse serum and in vivo using CXCR4 positive and negative tumor xenograft models. RESULTS: Labeling of Al[(18)F]NOTA-T140 was completed within 30 min with a radiochemical yield of 58 ± 5.3 % at the end of synthesis, based on fluoride-18 activity. Al[(18)F]NOTA-T140 accumulated in CHO-CXCR4 positive but not negative tumors. Al[(18)F]NOTA-T140 uptake in the tumors correlated with CXCR4 protein expression. Moreover, Al[(18)F]NOTA-T140 had high accumulation in CXCR4-positive metastatic tumors. CONCLUSIONS: The simplicity of Al[(18)F]NOTA-T140 labeling along with its properties to specifically image CXCR4 expression by tumors warrant further clinical application for the diagnosis of CXCR4 clinically.
Authors: William J McBride; Robert M Sharkey; Habibe Karacay; Christopher A D'Souza; Edmund A Rossi; Peter Laverman; Chien-Hsing Chang; Otto C Boerman; David M Goldenberg Journal: J Nucl Med Date: 2009-05-14 Impact factor: 10.057
Authors: Orit Jacobson; Ido D Weiss; Lawrence Szajek; Joshua M Farber; Dale O Kiesewetter Journal: Bioorg Med Chem Date: 2009-01-15 Impact factor: 3.641
Authors: Orit Jacobson; Ido D Weiss; Lawrence P Szajek; Gang Niu; Ying Ma; Dale O Kiesewetter; Joshua M Farber; Xiaoyuan Chen Journal: Theranostics Date: 2011-04-19 Impact factor: 11.556
Authors: Hans Jürgen Wester; Ulrich Keller; Margret Schottelius; Ambros Beer; Kathrin Philipp-Abbrederis; Frauke Hoffmann; Jakub Šimeček; Carlos Gerngross; Michael Lassmann; Ken Herrmann; Natalia Pellegata; Martina Rudelius; Horst Kessler; Markus Schwaiger Journal: Theranostics Date: 2015-03-01 Impact factor: 11.556
Authors: Yongfeng Zhao; Lisa Detering; Deborah Sultan; Matthew L Cooper; Meng You; Sangho Cho; Stephanie L Meier; Hannah Luehmann; Guorong Sun; Michael Rettig; Farrokh Dehdashti; Karen L Wooley; John F DiPersio; Yongjian Liu Journal: ACS Nano Date: 2016-05-18 Impact factor: 15.881
Authors: Malte Kircher; Peter Herhaus; Margret Schottelius; Andreas K Buck; Rudolf A Werner; Hans-Jürgen Wester; Ulrich Keller; Constantin Lapa Journal: Ann Nucl Med Date: 2018-08-13 Impact factor: 2.668
Authors: Falguni Basuli; Xiang Zhang; Tim E Phelps; Elaine M Jagoda; Peter L Choyke; Rolf E Swenson Journal: Molecules Date: 2020-08-27 Impact factor: 4.411